Cancidas, Cancidas (previously caspofungin msd)(caspofungin)
Cancidas, Caspofungin (caspofungin) is a small molecule pharmaceutical. Caspofungin was first approved as Cancidas on 2001-01-26. It is used to treat aspergillosis, candidemia, and mycoses in the USA. It has been approved in Europe to treat aspergillosis and candidiasis.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Caspofungin (discontinued: Cancidas, Caspofungin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Caspofungin acetate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CASPOFUNGIN ACETATE | Fresenius Kabi | N-206110 RX | 2016-12-30 | 2 products |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cancidas | New Drug Application | 2024-10-11 |
| caspofungin acetate | ANDA | 2025-08-26 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| candidemia | EFO_1001282 | D058387 | — |
| mycoses | — | D009181 | B35-B49 |
| aspergillosis | EFO_0007157 | D001228 | B44 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Caspofungin Acetate, Caspofungin Acetate, Fresenius Kabi Usa | |||
| 9636407 | 2032-12-21 | DP | |
HCPCS
Code | Description |
|---|---|
| J0637 | Injection, caspofungin acetate, 5 mg |
Clinical
Clinical Trials
89 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Invasive candidiasis | D058365 | EFO_1001283 | B37 | — | 3 | 1 | 1 | — | 5 |
| Aspergillosis | D001228 | EFO_0007157 | B44 | — | 3 | — | 1 | — | 4 |
| Invasive pulmonary aspergillosis | D055744 | — | B44.0 | — | — | — | 1 | — | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | — | 1 | — | 1 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | — | — | 1 | — | 1 |
| Obstructive lung diseases | D008173 | — | — | — | — | — | 1 | — | 1 |
| Pulmonary aspergillosis | D055732 | EFO_1001834 | — | — | — | — | 1 | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Candidiasis | D002177 | — | B37 | — | 5 | — | — | 1 | 6 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | 1 | 2 |
| Fungemia | D016469 | — | B49 | — | 1 | — | — | — | 1 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | — | 1 |
| Invasive fungal infections | D000072742 | — | — | — | 1 | — | — | — | 1 |
| Liver transplantation | D016031 | EFO_0010682 | — | — | 1 | — | — | — | 1 |
| Hematopoietic stem cell transplantation | D018380 | — | — | — | 1 | — | — | — | 1 |
| Neutropenia | D009503 | — | D70 | — | 1 | — | — | — | 1 |
| Fever | D005334 | — | R50.9 | — | 1 | — | — | — | 1 |
| Oral candidiasis | D002180 | EFO_0007406 | B37.0 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Candidemia | D058387 | EFO_1001282 | — | — | — | — | — | 1 | 1 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | — | — | 1 | 1 |
| Shock | D012769 | — | R57.1 | — | — | — | — | 1 | 1 |
| Esophageal diseases | D004935 | EFO_0009544 | K22.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Caspofungin |
| INN | caspofungin |
| Description | Caspofungin (INN; brand name Cancidas) is a lipopeptide antifungal drug from Merck & Co., Inc.. It is a member of a class of antifungals termed the echinocandins. It works by inhibiting the enzyme (1→3)-β-D-glucan synthase and thereby disturbing the integrity of the fungal cell wall.
|
| Classification | Small molecule |
| Drug class | antifungal antibiotics (undefined group) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O |
Identifiers
| PDB | — |
| CAS-ID | 162808-62-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL499808 |
| ChEBI ID | 474180 |
| PubChem CID | 16119814 |
| DrugBank | DB00520 |
| UNII ID | F0XDI6ZL63 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Cancidas – Merck & Co
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 13,222 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,987 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use